Pink Sheet reports on Aranesp and Procrit concerns

Share this article:
Members of the FDA's Oncologic Drugs Advisory Committee expressed concerns at a May meeting that DTC advertising of Amgen's Aranesp and Johnson & Johnson's Procrit have given patients a lopsided impression of the drugs' risk/benefit profile, The Pink Sheet reported. The state of New York subpoenaed Aranesp promotional materials that month.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.